+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The choice of hormone replacement therapy or statin therapy in the treatment of hyperlipidemic postmenopausal women



The choice of hormone replacement therapy or statin therapy in the treatment of hyperlipidemic postmenopausal women



Atherosclerosis Suppl.s 3(1): 53-63



Evidence based treatment of cardiovascular risk factors on outcome in women is still inconclusive given the very large numbers needed to achieve a significant difference in cardiovascular event. Although numerous studies of the effect of hormone replacement therapy (HRT) on risk factors have suggested benefit, the only data from a randomised control trial of HRT in secondary prevention was neutral. Coronary disease-primary prevention: (a) Statins: Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEX CAPS). The only randomised controlled trial (RCT) to include women. There were fewer coronary heart disease (CHD) events in women but no difference in mortality. (b) HRT: no completed RCT-the results from Womens Health Initiative (WHI) and Women Intervention Study of Long Duration of Oestrogen in the Menopause (WISDOM) are awaited, the former likely to complete in 2004. There are numerous reports of positive observational epidemiological studies for HRT. There is little evidence for statin use in women who will probably not qualify for treatment on global CHD risk assessment, familial hypercholesterolaemia and type 2 diabetes excepted. HRT is, therefore, not only appropriate for its multiple effects on lipoproteins, vascular function and insulin sensitivity but also for prevention of osteoporosis. Coronary disease-secondary prevention: (a) Statins: the major measurable effect of these drugs is to reduce total and LDL cholesterol. In RCT trials, the Scandanavian Simvastatin Survival Study (4S), the Cholesterol and Recurrent Event (CARE) and Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID), approximately 20% of subjects were female, in whom CHD events, but not CHD or total mortality were reduced. (b) HRT: there is data available from a single RCT of continuous combined premarin and medroxyprogesterone acetate (MPA) against placebo, The Heart Estrogen Replacement Study (HERS). A study of 2763 women and mean duration of 4.1 years. This study was neutral, with no reduction in CHD events or mortality. There were more events in the first year, and fewer in years 3-5. Other studies of HRT have been observational and positive for HRT. The effects of treatment on lipoproteins with statins, HRT and combination of statin and HRT have been investigated. In secondary prevention for hyperlipidemic women to achieve cholesterol <5, low density lipoprotein (LDL) <3 mmol/l statins will be first choice, possibly with HRT additionally for its other benefits on cardiovascular risk factors.

(PDF emailed within 0-6 h: $19.90)

Accession: 011482723

Download citation: RISBibTeXText

PMID: 12044587

DOI: 10.1016/s1567-5688(01)00009-5


Related references

Coronary heart disease risk reduction in postmenopausal women: the role of statin therapy and hormone replacement therapy. Preventive Cardiology 7(3): 131-136, 2004

Fluctuations of lipid and lipoprotein levels in hyperlipidemic postmenopausal women receiving hormone replacement therapy. Archives of Internal Medicine 158(16): 1803-1806, 1998

Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. Journal of Cardiovascular Medicine 10(1): 85-92, 2009

Does hormone replacement therapy affect the use of prescription medicines in postmenopausal women: experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757. Bjog 114(5): 548-554, 2007

Study of tumor S-phase in postmenopausal women diagnosed with breast cancer while using hormone replacement therapy vs those never having used hormone replacement therapy. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 203, 1996

Hormone replacement therapy does not prevent coronary heart disease and is associated with increased overall risk for health of postmenopausal women. Final results of studies on hormone replacement therapy efficacy in frame of Women's Health Initiative and data from other recent studies. Kardiologiia 43(9): 77-79, 2004

A decision tree for the use of estrogen replacement therapy or hormone replacement therapy in postmenopausal women: consensus opinion of The North American Menopause Society. Menopause 7(2): 76-86, 2000

A Decision Tree for the Use of Estrogen Replacement Therapy or Hormone Replacement Therapy in Postmenopausal Women. Menopause 7(2): 76-86, 2000

Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy. Calcified Tissue International 83(2): 85-92, 2008

Transdermal nicotine use in postmenopausal women: does the treatment efficacy differ in women using and not using hormone replacement therapy?. Nicotine and Tobacco Research 6(5): 777-788, 2005

Transdermal nicotine use in postmenopausal women: Does the treatment efficacy differ in women using and not using hormone replacement therapy?. Nicotine & Tobacco Research 6(5): 777-788, 2004

Contemporary views on use of estrogen replacement therapy in postmenopausal women. I. Hormone therapy in women with menopausal osteoporosis. Ginekologia Polska 66(1): 28-31, 1995

Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolaemia among postmenopausal women. Journal of Internal Medicine 238(1): 39-47, 1995

Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolemia among postmenopausal women. Journal of Internal Medicine 238(1): 39-47, 1995

Efficacy of treatment with combined hormone replacement therapy for hyperlipidemia among postmenopausal women. Circulation 90(4 PART 2): I363, 1994